Randomized comparison of long-term desmopressin and alarm treatment for bedwetting.

Evans J, Malmsten B, Maddocks A, Popli HS, Lottmann H

Journal of pediatric urology25 Jun 2010Cited by 31 (Europe PMC)

PMID20579938DOI10.1016/j.jpurol.2010.04.018PepBankPUB-20579938

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialOther
In patients with severe enuresis, 7% receiving desmopressin withdrew early versus 32% receiving alarm, preventing evaluation of their data.
In plain wordsIn patients with severe bedwetting, early withdrawal occurred in 7% with desmopressin versus 32% with alarm.
Peptide
Desmopressin
Outcome
DecreaseEarly withdrawal
Study
n = 251
Comparator
Enuresis alarm
Outcome group
Treatment adherence and retention · Whole body
Studied dose
0.2-0.4 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Patients who withdrew early
7%
desmopressin
Patients who withdrew early
32%
enuresis alarm
Source sentences
Summary
Data could not be evaluated for the 32% of alarm patients and 7% of desmopressin patients who withdrew early.
2 context sentences(design, population, supporting numbers)
Summary · context
A 6-month randomized trial was performed with patients from 29 enuresis clinics: 251 patients ≥ 5 years in age with severe PNE (mean 5.5-5.6 wet nights/week) were randomized to desmopressin (0.2-0.4 mg daily) or alarm.
Summary · context
Efficacy analyses were performed using the intent-to-treat population (all patients) and excluding patients who withdrew; 12-month follow-up data were collected.
Report a problemFND-2057993801
02HumanRandomized controlled trialEfficacy outcome
In severe enuresis, similar proportions achieved at least 50% wet-night reduction with desmopressin and alarm (37.5% versus 32.2%).
In plain wordsIn patients with severe bedwetting, desmopressin and alarm had similar rates of at least 50% fewer wet nights.
Peptide
Desmopressin
Outcome
Direction not reportedAt least 50% wet-night reduction
Study
n = 251
Comparator
Enuresis alarm
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.2-0.4 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Patients with at least 50% reduction in wet nights/week
37.5%
desmopressin, intent-to-treat
Patients with at least 50% reduction in wet nights/week
32.2%
enuresis alarm, intent-to-treat
Source sentences
Summary
In intent-to-treat analyses, a similar proportion of patients across groups showed a ≥ 50% reduction in wet nights/week (desmopressin: 37.5%, alarm: 32.2%) and achieved dryness (desmopressin: 32%, alarm: 37%).
2 context sentences(design, population, supporting numbers)
Summary · context
A 6-month randomized trial was performed with patients from 29 enuresis clinics: 251 patients ≥ 5 years in age with severe PNE (mean 5.5-5.6 wet nights/week) were randomized to desmopressin (0.2-0.4 mg daily) or alarm.
Summary · context
Efficacy analyses were performed using the intent-to-treat population (all patients) and excluding patients who withdrew; 12-month follow-up data were collected.
Report a problemFND-2057993802
03HumanRandomized controlled trialEfficacy outcome
In severe enuresis, similar proportions achieved dryness with desmopressin and alarm (32% versus 37%).
In plain wordsIn patients with severe bedwetting, dryness rates were similar with desmopressin and alarm.
Peptide
Desmopressin
Outcome
Direction not reportedDryness
Study
n = 251
Comparator
Enuresis alarm
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.2-0.4 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Patients achieving dryness
32%
desmopressin, intent-to-treat
Patients achieving dryness
37%
enuresis alarm, intent-to-treat
Source sentences
Summary
In intent-to-treat analyses, a similar proportion of patients across groups showed a ≥ 50% reduction in wet nights/week (desmopressin: 37.5%, alarm: 32.2%) and achieved dryness (desmopressin: 32%, alarm: 37%).
2 context sentences(design, population, supporting numbers)
Summary · context
A 6-month randomized trial was performed with patients from 29 enuresis clinics: 251 patients ≥ 5 years in age with severe PNE (mean 5.5-5.6 wet nights/week) were randomized to desmopressin (0.2-0.4 mg daily) or alarm.
Summary · context
Efficacy analyses were performed using the intent-to-treat population (all patients) and excluding patients who withdrew; 12-month follow-up data were collected.
Report a problemFND-2057993803
04HumanRandomized controlled trialOther
In severe enuresis, 95-98% took more than 75% of desmopressin tablets versus 50-78% using alarm on more than 75% of nights.
In plain wordsIn patients with severe bedwetting, compliance was higher with desmopressin than alarm.
Peptide
Desmopressin
Outcome
IncreaseCompliance
Study
n: not reported in source
Comparator
Enuresis alarm
Outcome group
Treatment adherence and retention · Whole body
Studied dose
0.2-0.4 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Patients taking >75% of tablets
95 to 98%
desmopressin
Patients using alarm >75% of nights
50 to 78%
enuresis alarm
Source sentences
Summary
Compliance was higher with desmopressin: 95-98% of patients took >75% of tablets; 50-78% used alarm >75% of nights.
2 context sentences(design, population, supporting numbers)
Summary · context
A 6-month randomized trial was performed with patients from 29 enuresis clinics: 251 patients ≥ 5 years in age with severe PNE (mean 5.5-5.6 wet nights/week) were randomized to desmopressin (0.2-0.4 mg daily) or alarm.
Summary · context
Efficacy analyses were performed using the intent-to-treat population (all patients) and excluding patients who withdrew; 12-month follow-up data were collected.
Report a problemFND-2057993804
05HumanRandomized controlled trialEfficacy outcome
In severe enuresis, initial sleep duration was 1.02 h longer with desmopressin than alarm at treatment end (95% CI 0.045, 1.99).
In plain wordsIn patients with severe bedwetting, initial sleep lasted 1.02 h longer with desmopressin than alarm at treatment end.
Peptide
Desmopressin
Outcome
IncreaseInitial sleep duration
Study
n: not reported in source
Comparator
Enuresis alarm
Outcome group
Sleep · Sleep
Studied dose
0.2-0.4 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Longer initial sleep duration, desmopressin versus alarm
1.02 h
end of treatment
95% confidence interval of difference in initial sleep duration
0.045 to 1.99 h
end of treatment
Source sentences
Summary
Initial sleep duration was 1.02 h longer at the end of treatment with desmopressin (95% CI: 0.045, 1.99).
2 context sentences(design, population, supporting numbers)
Summary · context
A 6-month randomized trial was performed with patients from 29 enuresis clinics: 251 patients ≥ 5 years in age with severe PNE (mean 5.5-5.6 wet nights/week) were randomized to desmopressin (0.2-0.4 mg daily) or alarm.
Summary · context
Efficacy analyses were performed using the intent-to-treat population (all patients) and excluding patients who withdrew; 12-month follow-up data were collected.
Report a problemFND-2057993805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.